Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05125523
Other study ID # HB1901-CSP-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 28, 2021
Est. completion date November 2024

Study information

Verified date November 2021
Source CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Contact Xuekun Yao
Phone 0311-67808678
Email yaoxuekun@mail.ecspc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to estimate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of Sirolimus for Injection (Albumin Bound) in patients with solid malignancies.


Description:

This study will be conducted in two stages. Stage 1: To evaluate the safety and tolerability of Sirolimus for Injection (Albumin Bound) in patients with advanced tumors, determine the MTD and RP2D. The dose escalation scheme using the accelerated titration design for dose 1 and the rolling-six design for the remaining doses. Stage 2: To preliminarily assess the antitumor activity of Sirolimus for Injection (Albumin Bound). Patients will be assigned to different cohorts based on their tumor type.


Recruitment information / eligibility

Status Recruiting
Enrollment 264
Est. completion date November 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age 18-75 years (inclusive), no gender limitation. 2. Patients must have a histologically or cytologically confirmed advanced or metastatic tumor for which no effective standard therapy is available, or have failed or been intolerant to standard therapies. 3. At least one measurable lesion per RECIST version 1.1. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2. 5. Life expectancy of =3 months. 6. Suitable organs and hematopoietic function should be available. Laboratory tests during screening should meet the appropriate criteria. 7. Signed informed consent form. Exclusion Criteria: 1. Prior anticancer treatment or participation in another clinical study within 4 weeks (or 5 half-lives of the treated drug, whichever is longer) prior to the first dose of study drugs. 2. Patients who have undergone major surgery within 4 weeks prior to starting study treatment, or who have not fully recovered from previous surgery. 3. Unresolved toxicities from prior therapy greater than Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) (except alopecia or any other toxicity without safety risks as judged by the investigator). 4. History of serious cardiovascular disease. 5. Central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence that the patient's central nervous system metastasis or meningeal metastasis has not been controlled, and the investigator judges it to be unsuitable for inclusion. 6. Known prior hypersensitivity to study drugs or any component in their formulations. 7. Prior treatment with any mTOR inhibitor. 8. Has received a live or live-attenuated virus vaccine within 30 days prior to consent. 9. Uncontrollable active infection (CTCAE v5.0 =grade 2). 10. Use of strong inhibitors and inducers of CYP3A4 within 2 weeks prior to receiving the first dose of study drug and still need to continue using this class of drug. 11. History of autoimmune diseases, immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency, or organ transplant history. 12. HBsAg-positive with HBV viral load (VL) =1000 IU/mL; Hepatitis C Virus (HCV)-positive; Anti-treponema pallidum positive. 13. Women of child-bearing potential, or men whose partners are women of childbearing age, have not agree to use highly effective methods of contraception during dosing and for 6 months after study drug discontinuation; female patients has a positive serum pregnancy test within 7 days prior to receiving the first dose of study medication; lactating female. 14. Has history of other serious diseases judged by the investigator, which will threaten the safety of patients or interfere the study compliance, or other reasons are not suitable for participating in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sirolimus for Injection (Albumin Bound)
Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)

Locations

Country Name City State
China Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events Up to 3 years
Primary Dose-Limiting Toxicities (Stage 1) Cycle 1 (Up to 28 days)
Primary Maximum tolerated dose (Stage 1) Up to 1.5 years
Primary Recommended phase 2 dose (Stage 1) Up to 1.5 years
Primary Overall response rate (Stage 2) Up to 3 years
Secondary Area under the plasma concentration versus time curve (AUC) Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Secondary Peak concentration (Cmax) Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Secondary Peak time (Tmax) Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Secondary Distribution volume (Vz) Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Secondary Elimination half-life (t1/2) Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Secondary Clearance (CL) Day 1 of cycle 1 to Day 1 of cycle 4 (85 days)
Secondary Disease Control Rate Up to 3 years
Secondary Duration of Response Up to 3 years
Secondary Progression-free Survival Up to 3 years
Secondary 4ebp-1 phosphorylation level in blood samples Up to 168 hours post dose
Secondary S6K phosphorylation level in blood samples Up to 168 hours post dose
Secondary TSC1/2 status in tumor samples Day 1 of cycle 1
Secondary PTEN status in tumor samples Day 1 of cycle 1
Secondary PIK3CA status in tumor samples Day 1 of cycle 1
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1
Completed NCT00962091 - Study of MLN8237 in Participants With Advanced Solid Tumors Phase 1